Repligen Corporation Stock News

Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up peri

Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares jumped 364.3% to $23.22. The company offered shares at an expected price of $5.00 per share with an insider lock-up period of 180 days endin

Universal Health's (UHS) second-quarter results are likely to benefit from sound contributions from Acute Care Hospital Services segment. Increased labor costs might partly hurt results.

Webcast and Conference Call to Be Held Tuesday, August 2, 2022 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Tuesday, August 2, 2022 at 8:30 a.m. EDT

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

WALTHAM, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participati

The declining pace of COVID-19 vaccination programs is likely to hurt Repligen's (RGEN) revenue growth rate in 2022. However, the strong core business is likely to offer a respite.

Last summer I first covered Repligen, a company that develops tools and services for manufacturing biologics. While bad timing in regards to short-term performance, I reiterate my Strong Buy view of t

Repligen (RGEN) reports encouraging first-quarter results with both sales and earnings beating estimates. RGEN also reduced its financial guidance for 2022

Repligen (RGEN) reports encouraging first-quarter results with both sales and earnings beating estimates. RGEN also reduced its financial guidance for 2022

Needham lowered MKS Instruments, Inc. (NASDAQ: MKSI) price target from $185 to $175. MKS Instruments shares rose 3.6% to $116.01 in pre-market trading. Piper Sandler cut the price target for PayPal

A stronger-than-expected earnings report calls months of the stock's weakness into question.

Repligen Corporation (NASDAQ:RGEN ) Q1 2022 Results Earnings Conference Call April 27, 2022 8:30 AM ET Company Participants Sondra Newman - Vice President and Global Head of Investor Relations Tony Hu

Repligen (RGEN) delivered earnings and revenue surprises of 27.78% and 12.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Favored companies include Uber, General Motors and Twilio.